Metformin for chemoprevention of lung cancer in obese subjects at high risk
Description: PROJECT NARRATIVE Despite several ground-breaking advances in the treatment of lung cancer, the overall outlook remains dismal, necessitating the urgent development of preventive therapies. We have observed that use of the anti-diabetic drug metformin is associated with improved lung cancer outcomes selectively in patients who are overweight and obese and have linked this association to metformin-induced immunological changes in both humans and mice. With a clinical trial and mouse experiments, we propose to study if the anti-cancer immune effect of metformin occurs in obese subjects who have a high risk for developing lung cancer occurs so that the drug may be used for cancer prevention.
Funder: National Cancer Institute
Funding type: research
Funder scheme: R01
Start date: 2021-08-01
End date: 2027-07-31
Investigator: JOSEPH BARBI
Institution: ROSWELL PARK CANCER INSTITUTE CORP
Funded outputs count: 13
Funder award ID: R01CA255515
OpenAlex ID: G9000892914